This proposal is a combined R&D and demonstration project aimed at developing a novel therapeutic substance effective as cancer vaccine. The consortium has a unique expertise in a novel cell free vaccine i.e. the exosomes, 60-90 nm antigen presenting membrane vesicles of endosomal origin, secreted by antigen presenting cells. Characterization of exosome bioactivity will allow neosynthesis of biovectors endowed with targeting and tumor antigen transfer capacities to antigen presenting cells for active immunization. R&D objectives will be to:
1) define the biogenesis and biochemica composition of exasomes.
2) investigate their in vitra and in viva functians.
3) optimise the immunizing strategy using exosomes in preclinical tumor studies
4) design "universal" exosome based-cancer vaccine using good manufactoring procedures.
Demonstration phase involving the SME will show exosome safety and efficacy in immunizing metastatic cancer bearing patients.
Funding SchemeDEM - Demonstration contracts
2311 EZ Leiden
CF14 2TL Cardiff